← Back to Screener
Cytokinetics Inc. (CYTK)
Price$65.42
Favorite Metrics
Price vs S&P 500 (26W)3.50%
Price vs S&P 500 (4W)-0.71%
Market Capitalization$8.05B
All Metrics
Book Value / Share (Quarterly)$0.92
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-2.37%
Cash Flow / Share (Quarterly)$-4.35
Price vs S&P 500 (YTD)0.24%
Net Profit Margin (TTM)-891.60%
EPS (TTM)$-6.53
10-Day Avg Trading Volume1.67M
EPS Excl Extra (TTM)$-6.53
Revenue Growth (5Y)9.55%
EPS (Annual)$-6.54
ROI (Annual)-55.49%
Net Profit Margin (5Y Avg)-2357.67%
Cash / Share (Quarterly)$7.18
Revenue Growth QoQ (YoY)4.89%
ROA (Last FY)-55.10%
Revenue Growth TTM (YoY)376.56%
EBITD / Share (TTM)$-6.02
ROE (5Y Avg)-141.97%
Operating Margin (TTM)-833.16%
Cash Flow / Share (Annual)$-4.35
P/B Ratio73.86x
P/B Ratio (Quarterly)58.24x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)94.57x
Net Interest Coverage (TTM)-14.32x
ROA (TTM)-58.68%
EV / EBITDA (TTM)993.49x
EPS Incl Extra (Annual)$-6.54
Current Ratio (Annual)4.53x
Quick Ratio (Quarterly)4.45x
3-Month Avg Trading Volume1.93M
52-Week Price Return64.20%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-4.56
P/S Ratio (Annual)91.44x
Asset Turnover (Annual)0.06x
52-Week High$70.98
Operating Margin (5Y Avg)-2191.85%
EPS Excl Extra (Annual)$-6.54
CapEx CAGR (5Y)17.56%
26-Week Price Return7.48%
Quick Ratio (Annual)4.45x
13-Week Price Return1.13%
Total Debt / Equity (Annual)0.59x
Current Ratio (Quarterly)4.53x
Enterprise Value$8,325.478
Revenue / Share Growth (5Y)-3.26%
Asset Turnover (TTM)0.07x
Book Value / Share Growth (5Y)10.66%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-891.60%
Cash / Share (Annual)$7.18
3-Month Return Std Dev40.19%
Net Income / Employee (TTM)$-1
ROE (Last FY)-88.27%
Net Interest Coverage (Annual)-14.32x
EPS Basic Excl Extra (Annual)$-6.54
P/FCF (TTM)140.33x
Receivables Turnover (TTM)5.12x
Total Debt / Equity (Quarterly)6.01x
EPS Incl Extra (TTM)$-6.53
Receivables Turnover (Annual)5.12x
ROI (TTM)-18.72%
P/S Ratio (TTM)91.44x
Pretax Margin (5Y Avg)-2357.67%
Revenue / Share (Annual)$0.73
Tangible BV / Share (Annual)$-1.14
Price vs S&P 500 (52W)34.37%
Year-to-Date Return2.88%
5-Day Price Return1.21%
EPS Normalized (Annual)$-6.54
ROA (5Y Avg)-44.98%
Net Profit Margin (Annual)-891.60%
Month-to-Date Return-0.82%
Cash Flow / Share (TTM)$-5.44
EBITD / Share (Annual)$-6.02
Operating Margin (Annual)-833.16%
LT Debt / Equity (Annual)0.59x
ROI (5Y Avg)-67.84%
LT Debt / Equity (Quarterly)5.90x
EPS Basic Excl Extra (TTM)$-6.53
P/B Ratio (Annual)15.68x
Pretax Margin (TTM)-891.60%
Book Value / Share (Annual)$2.88
Price vs S&P 500 (13W)0.44%
Beta0.38x
P/FCF (Annual)227.54x
Revenue / Share (TTM)$0.72
ROE (TTM)-131.19%
52-Week Low$29.31
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.04
4.04
4.04
4.04
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CYTKCytokinetics Inc. | 91.44x | 376.56% | — | — | $65.42 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Cytokinetics is a late-stage biopharmaceutical company developing small-molecule muscle activators and inhibitors for serious cardiovascular and neuromuscular diseases, including heart failure, amyotrophic lateral sclerosis, spinal muscular atrophy, and chronic obstructive pulmonary disease. Its investigational medicines enhance muscle function and contractility in patients with compromised muscle performance. The company targets large patient populations with significant unmet medical needs and limited treatment options.